Company Overview of Federal Trade Commission
600 Pennsylvania Avenue
Washington, DC 20580
Key Executives for Federal Trade Commission
Chair of Covington's Antitrust and Consumer Law Practice Group
Acting Chief Information Officer
Compensation as of Fiscal Year 2015.
Federal Trade Commission Key Developments
The U.S. Federal Trade Commission Approves Dollar Tree Inc.'s Proposal of $9.2 Billion Acquisition of Family Dollar Stores Inc
Jul 3 15
The U.S. Federal Trade Commission approved Dollar Tree Inc.'s (DLTR) proposed $9.2 billion acquisition of Family Dollar Stores Inc. (FDO), on the condition that 330 Family Dollar stores are sold to Sycamore Partners to alleviate competition concerns. The FTC announced both Dollar Tree and Family Dollar sell deeply discounted general merchandise items. The regulator identified 330 stores in local markets from 35 states where competition would be lost if the acquisition went forward as proposed.
Federal Trade Commission Issues Final Order Preserving Supermarket Competition in 130 Local Markets Albertsons and Safeway Required to Sell 168 Stores in Eight States
Jul 2 15
Federal Trade Commission has approved a final order settling charges that the $9.2 billion merger of Albertsons and Safeway Inc. would be anticompetitive. FTC announced in January 2015, Albertsons and Safeway grocery stores competed vigorously on price, quality, product variety, and services, and each offered consumers the convenience of one-stop shopping for food and other grocery products. Without a remedy, the acquisition was likely to lessen supermarket competition in 130 local markets and thus harm consumers. The final order requires the new company to divest 168 Albertsons and Safeway stores in Arizona, California, Montana, Nevada, Oregon, Texas, Washington, and Wyoming to four buyers.
Teva Pharmaceutical Industries Agrees to Pay $1.2 Billion to Settle a Federal Trade Commission Allegation
Jun 8 15
Teva Pharmaceutical Industries has agreed to pay $1.2 billion to settle a Federal Trade Commission allegation that its Cephalon subsidiary illegally blocked the launch of low-cost generic versions of its blockbuster sleep-disorder drug Provigil. The settlement stems from a 2008 FTC lawsuit, which charged that Cephalon unlawfully protected its Provigil monopoly through a series of agreements with four generic drug manufacturers in late 2005 and early 2006. FTC alleged that Cephalon sued the generic drug makers for patent infringement and later paid them more than $300 million in total to drop their patent challenges and forgo marketing their generic products for six years, until April 2012. Were it not for the deals, the drug would have faced competition in 2006, reducing costs for consumers. Under the settlement, Teva will pay $1.2 billion to compensate purchasers, including drug wholesalers, pharmacies, and insurers, who overpaid for Provigil. FTC will allow Teva to count its settlement with direct purchasers in related litigation as a credit toward the total amount paid to the commission.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|
Most Searched Private Companies
Sponsored Financial Commentaries